Xynos Konstantinos sold $148K of REPL

Xynos Konstantinos (Chief Medical Officer) sold 11,447 shares of Replimune Group, Inc. (REPL) at $12.97 ($0.15M total) on 2026-08-10.

Original reporting
SEC EDGAR · Xynos Konstantinos
Published Aug 12, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Neutral
medium confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLNeutralLow
01

Why it matters

This provides a fresh datapoint on insider behavior (CMO selling 11,447 shares) but no new company fundamentals, guidance, or regulatory/clinical milestones.

02

Market read

Traders may monitor insider activity, but the disclosure alone is unlikely to drive a durable repricing without corroborating fundamental news.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; the filing does not indicate intent to change strategy or company outlook.

Relevance 4/10Novelty 3/10Timing: filed Aug 12, covering a sale executed Aug 10

Background

The article is a SEC Form 4 insider transaction disclosure for Replimune Group, Inc.

Company-level read

Ticker impact

$REPLNeutralMedium confidence
Context

Replimune Group disclosed an insider open-market sale by CMO Xynos Konstantinos of 11,447 shares at $12.97 on Aug 10.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider transactions are common and typically not predictive without accompanying company-specific news; the article provides sale size, price, and post-transaction holdings only.

Market effects

Minimal, as this is company-specific insider selling with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted as less “pre-scheduled” selling, which some traders may read as near-term caution.

Key entities

  • Replimune Group, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Xynos Konstantinos

    Chief Medical Officer who sold shares in an open-market transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.